Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.6%

4 terminated/withdrawn out of 61 trials

Success Rate

89.5%

+3.0% vs industry average

Late-Stage Pipeline

31%

19 trials in Phase 3/4

Results Transparency

6%

2 of 34 completed trials have results

Key Signals

6 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
18(36.0%)
Phase 3
11(22.0%)
Phase 1
10(20.0%)
Phase 4
8(16.0%)
N/A
3(6.0%)
50Total
Phase 2(18)
Phase 3(11)
Phase 1(10)
Phase 4(8)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (61)

Showing 20 of 61 trials
NCT05762393Phase 1Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar

Role: lead

NCT07270796Phase 1Not Yet Recruiting

Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants

Role: lead

NCT07416461Recruiting

Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease

Role: lead

NCT07377656Phase 2Not Yet Recruiting

Strengthening HPV Immunization Through EPI Leveraged Delivery

Role: lead

NCT07304284Phase 3Recruiting

Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus

Role: lead

NCT07093489Not Yet Recruiting

Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)

Role: lead

NCT06129253Recruiting

Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)

Role: lead

NCT04566484Phase 2Terminated

Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia

Role: lead

NCT06306196Phase 2Recruiting

Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children

Role: lead

NCT05559983Phase 1Completed

Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults

Role: lead

NCT06800131Phase 1Not Yet Recruiting

Hepatitis B Vaccine Delivered Trans-dermally by MAP

Role: lead

NCT05501522Phase 3Completed

Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older

Role: collaborator

NCT05808166Phase 2Recruiting

Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women

Role: lead

NCT05007951Phase 3Completed

Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

Role: collaborator

NCT04852185Phase 4Recruiting

Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana

Role: lead

NCT05710289Withdrawn

A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.

Role: collaborator

NCT04672395Phase 2Completed

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

Role: collaborator

NCT04760236Phase 3Completed

Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™

Role: lead

NCT05520970Phase 2Terminated

Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1

Role: collaborator

NCT03465254Unknown

Dengue Serostatus Study in the Philippines

Role: collaborator